Holen Sie sich die Stockscreener-App
0.8631
5.26%
0.0431
Handel nachbörslich:
.86
-0.0031
-0.36%
Iterum Therapeutics Plc Aktie (ITRM) Neueste Nachrichten
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcMarket Sentiment Summary & Breakout Confirmation Trade Signals - Newser
News impact scoring models applied to Iterum Therapeutics plcDay Trade & Technical Pattern Based Signals - Newser
Analyzing Iterum Therapeutics plc with multi timeframe charts2025 Price Targets & Entry Point Confirmation Alerts - Newser
Leading vs lagging indicators on Iterum Therapeutics plc performance2025 Fundamental Recap & Capital Protection Trading Alerts - Newser
Will Iterum Therapeutics plc continue its uptrend2025 Short Interest & Verified Technical Signals - Newser
What institutional flow reveals about Iterum Therapeutics plc2025 Winners & Losers & Real-Time Buy Signal Alerts - Newser
Iterum Therapeutics plc stock trend outlook and recovery path2025 Year in Review & Weekly Top Gainers Alerts - Newser
Using Bollinger Bands to evaluate Iterum Therapeutics plc2025 Retail Activity & Technical Buy Zone Confirmations - Newser
Is Iterum Therapeutics plc reversing from oversold territoryMarket Activity Report & Reliable Volume Spike Alerts - Newser
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call Transcript - MSN
Using data filters to optimize entry into Iterum Therapeutics plc2025 Top Decliners & Safe Capital Growth Tips - Newser
ITRM Reports Results - AOL.com
Using Ichimoku Cloud for Iterum Therapeutics plc technicalsTrade Volume Report & Scalable Portfolio Growth Methods - Newser
Chart based exit strategy for Iterum Therapeutics plc2025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - Newser
Price momentum metrics for Iterum Therapeutics plc explainedJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser
What’s next for Iterum Therapeutics plc stock priceLow Risk Stock Trade Opportunity Analysis - Newser
Using economic indicators to assess Iterum Therapeutics plc potentialStock Market Watch with Smart Filters - Newser
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares By Investing.com - Investing.com Australia
Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8. - AInvest
Real time pattern detection on Iterum Therapeutics plc stockSecure Buy Strategy Based on Risk Parameters - Newser
Why Iterum Therapeutics plc stock attracts strong analyst attentionLow Drawdown Picks with Weekly Updates - Newser
Developing predictive dashboards with Iterum Therapeutics plc dataFuture Growth Stock Forecasting Strategy - Newser
Will Iterum Therapeutics plc stock recover after recent dropReal Stock Picks With Setup Verification - Newser
Iterum Therapeutics (NASDAQ:ITRM) Downgraded by Wall Street Zen to “Sell” - Defense World
Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Up 54.6% in July - Defense World
ITRM Reports Results - The Motley Fool
Iterum Therapeutics PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Iterum Therapeutics (ITRM) Financial Outlook for 2025 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics reports Q2 results, launches ORLYNVAH, extends cash runway to 2026. - AInvest
Iterum Therapeutics to Launch ORLYNVAH™ for Uncomplicated UTIs in August 2025, Reports Q2 Financial Results - Quiver Quantitative
Iterum Therapeutics Reports Second Quarter 2025 Financial Results - The Manila Times
Iterum Therapeutics reports Q2 revenue, cash runway into 2026, ORLYNVAH launch in August. - AInvest
Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch - Stock Titan
Iterum Therapeutics (NASDAQ:ITRM) Shares Down 2.5% – Here’s Why - Defense World
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):